How can cannabis and cannabinoids help you? What the research says

Medical cannabis and cannabinoids in raw or dried flowers, oils, capsules, powders, edibles, and topicals may reduce pain, and some evidence shows benefit with nausea, vomiting, and sleep, but little evidence of improving treatment outcomes.

How can cannabis and cannabinoids help you? What the research says

We summarize the clinical evidence for each medical benefit here. We begin with our assessment of the strength of evidence within each category, followed by a brief summary of individual studies or reviews of several studies. In assessing the strength of evidence, we consider the study design, number of participants, and the size of the treatment effect (how much outcomes changed with treatment).

To see more details, click the plus sign to the right of any section.

Our assessments of evidence for each medical benefit fall into one of these categories:

Strong evidence: consistent, significant effects in several large (or at least one very large) well designed clinical studies or at least two meta-analysesa statistical analysis that combines the results of two or more research studies; the results of smaller research studies addressing the same or similar questions can be analyzed as though they are one bigger, more powerful study of clinical studies of moderate or better quality (or one large meta-analysis) finding similar results
Good evidence: significant effects in one large or several mid-sized and well-designed clinical studies ( randomized controlled trialsa study design in which people are randomly assigned to either an experimental group or a control group to compare the outcomes from different treatments; an RCT is considered a strong design for determining a therapy’s effects with an appropriate placebo or other strong comparison control or observational studies that control for confounds)
Modest evidence: significant effects in at least three small but well-designed randomized controlled trials (RCTs), or one or more well-designed, mid-sized clinical studies of reasonably good quality (RCTs or observationala type of study in which individuals are observed or certain outcomes are measured, but no attempt is made to affect the outcome (for example, no treatment is given); an example is a study that records people’s diets, but doesn’t try to alter their diets, and looks for patterns of disease or other outcomes related to different foods studies), or several small studies aggregated into a meta-analysis
Preliminary evidence: significant effects in small or poorly designed clinical studies OR conflicting results in adequate studies but a preponderance of evidence of an effect
Weak evidence: one or more case studies, supported by animal evidence OR small treatment effects of limited clinical significance OR studies with no controls OR weak trends of effects
Insufficient evidence: preclinical evidence only OR clinical studies with such poor or unclear methodology that no conclusion can be drawn OR conflicting findings across clinical studies with no preponderance of evidence in one direction; conflicting evidence occurs when studies find conflicting effects (positive effect vs no effect or negative effect) with the same treatment and the same general study population (same cancer type, for example)

Learn more about how we research and rate therapies and practices in How We Rate Therapies ›

A brief summary of preclinical evidence is in Are you a health professional? ›

Improving treatment outcomes

Is cannabis or cannabinoids linked to improved survival? Is it linked to less cancer growth or metastasis? Does it enhance the anticancer action of other treatments or therapies? We present the evidence.

Cancer as a whole

Weak evidenceone or more case studies, supported by animal evidence OR small treatment effects of limited clinical significance OR studies with no controls OR weak trends of effects (this is the CancerChoices definition; other researchers and studies may define this differently) of anticancer effects and reduced tumors

Brain cancer

Preliminary evidencesignificant effects in small or poorly designed clinical studies OR conflicting results in adequate studies but a preponderance of evidence of an effect (this is the CancerChoices definition; other researchers and studies may define this differently) of tumor response among people with recurrent glioblastoma multiforme treated with cannabis

Lung cancer

No evidence of an effectoverall, one or more studies did not demonstrate that a treatment or intervention led to an expected outcome; this does not always mean that there is no effect in clinical practice, but that the studies may have been underpowered (too few participants) or poorly designed. Larger, well-designed studies provide more confidence in making assessments. on time to tumor progression or survival after first-line monotherapy pembrolizumab among people with metastatic non-small cell lung cancer treated with cannabis

Optimizing your body terrain

Does cannabis or cannabinoids promote an environment within your body that is less supportive of cancer development, growth, or spread? We present the evidence.

See Optimizing Your Body Terrain ›

Find medical professionals who specialize in managing body terrain factors: Finding Integrative Oncologists and Other Practitioners ›

We also recommend that you share with your doctor the information here about how cannabis or cannabinoids might affect these terrain factors if you have any imbalances.

High blood sugar and insulin resistance

Preliminary evidencesignificant effects in small or poorly designed clinical studies OR conflicting results in adequate studies but a preponderance of evidence of an effect (this is the CancerChoices definition; other researchers and studies may define this differently) of lower blood sugar levels among people with type 2 diabetes treated with THCV

Your microbiome

Preliminary evidence of beneficial changes in the relative numbers of microbial species in the tongues of people without cancer with chronic inhalation-based exposure to cannabis

Managing side effects and promoting wellness

Is cannabis or cannabinoids linked to fewer or less severe side effects or symptoms? Is it linked to less toxicity from cancer treatment? Does it support your quality of life or promote general well-being? We present the evidence.

Side effects as a whole

No evidence of an effectoverall, one or more studies did not demonstrate that a treatment or intervention led to an expected outcome; this does not always mean that there is no effect in clinical practice, but that the studies may have been underpowered (too few participants) or poorly designed. Larger, well-designed studies provide more confidence in making assessments. on total symptom distress scores among people with advanced cancer treated with titrated CBD oil in a study

Anxiety

Insufficient evidencepreclinical evidence only OR clinical studies with such poor or unclear methodology that no conclusion can be drawn OR conflicting findings across clinical studies with no preponderance of evidence in one direction; conflicting evidence occurs when studies find conflicting effects (positive effect vs no effect or negative effect) with the same treatment and the same general study population (same cancer type, for example) (this is the CancerChoices definition; other researchers and studies may define this differently) of fewer anxiety symptoms among people with cancer using cannabis or cannabinoids

Changes in appetite

No evidence of an effect on appetite among people with cancer treated with cannabis or cannabinoids in several analyses of studies

Gastrointestinal effects

Modest evidencesignificant effects in at least three small but well-designed randomized controlled trials (RCTs), or one or more well-designed, mid-sized clinical studies of reasonably good quality (RCTs or observational studies), or several small studies aggregated into a meta-analysis (this is the CancerChoices definition; other researchers and studies may define this differently) of less chemotherapy-induced nausea and vomiting among people using cannabis or cannabinoids

Modest evidence of less vomiting among people treated with cannabinoids compared to neuroleptics (antipsychotic medication)

Modest evidence of comparable effects on nausea and vomiting among people treated with cannabinoids compared to prochlorperazine

Some studies found that pharmaceutical cannabinoids were less tolerated and less safe than placebo, as noted in Safety and precautions ›

Compared to placebo or controls: modest evidence of less chemotherapy-induced nausea and vomiting among people using cannabis or cannabinoids

Substantially less nausea and vomiting after antiemetic prophylaxis during moderately or highly emetogenic, intravenous chemotherapy among adults with refractory nausea and/or vomiting treated with tetrahydrocannabinol 2.5 mg plus cannabidiol 2.5 mg capsules 3 times a day on days 1 to 5 compared to placebo in a mid-sized RCTrandomized controlled trial, a study design in which people are randomly assigned to either an experimental group or a control group to compare the outcomes from different treatments; an RCT is considered a strong design for determining a therapy’s effects¹⁶Grimison P, Mersiades A et al. Oral cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: final results of a randomized, placebo-controlled, phase II/III trial. Journal of Clinical Oncology. 2024 Aug 16:JCO2301836.
Less chemotherapy-induced nausea and vomiting, but no evidence of an effectoverall, one or more studies did not demonstrate that a treatment or intervention led to an expected outcome; this does not always mean that there is no effect in clinical practice, but that the studies may have been underpowered (too few participants) or poorly designed. Larger, well-designed studies provide more confidence in making assessments. on nausea alone or vomiting alone, among people treated with oral cannabis compared to placebo or other treatments in a meta-analysisa statistical analysis that combines the results of two or more research studies; the results of smaller research studies addressing the same or similar questions can be analyzed as though they are one bigger, more powerful study of 5 RCTs¹⁷Chow R, Valdez C, Chow N, et al. Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting—a systematic review and meta-analysis. Supportive Care in Cancer. 2020;28:2095-2103.
A weak trendan apparent change due to a therapy, close to but not achieving full statistical significance (this is the CancerChoices definition; other researchers and studies may define this differently toward less nausea and vomiting among people with cancer treated with cannabis or cannabinoids compared to placebo in a meta-analysis of 9 RCTs and controlled trialsa study design in which people are assigned to either an experimental group or a control group to compare the outcomes from different treatment; assignment is not random, and so this is not as strong a study design as a randomized controlled trial, but still stronger than an uncontrolled trial¹⁸Mücke M, Carter C et al. Cannabinoide in der palliativen Versorgung: Systematische Übersicht und Metaanalyse der Wirksamkeit, Verträglichkeit und Sicherheit [Cannabinoids in palliative care: systematic review and meta-analysis of efficacy, tolerability and safety]. Schmerz. 2016 Feb;30(1):25-36. German.
Moderate quality evidence on the efficacy of cannabinoids compared to placebo for chemotherapy-induced nausea and vomiting in systematic reviews of randomized controlled trials;¹⁹Tafelski S, Häuser W, Schäfer M. Efficacy, tolerability, and safety of cannabinoids for chemotherapy-induced nausea and vomiting—a systematic review of systematic reviews. Schmerz. 2016;30:14-24. this study also found that pharmaceutical cannabinoids were less tolerated and less safe than placebo, as noted in Safety and precautions ›
Less chemotherapy-induced nausea and vomiting among people using cannabinoids compared to placebo in a systematic review of high methodological quality²⁰Schussel V, Kenzo L, Santos A, et al. Cannabinoids for nausea and vomiting related to chemotherapy: overview of systematic reviews. Phytotherapy Research. 2018;32:567-576.
No evidence of an effect on nausea and vomiting among people with cancer treated with cannabinoids compared to placebo in a meta-analysis of 9 RCTs of low quality²¹Mücke M, Weier M. Systematic review and meta-analysis of cannabinoids in palliative medicine. Journal of Cachexia, Sarcopenia and Muscle. 2018 Apr;9(2):220-234.
Higher likelihood of a complete absence of vomiting, either with or without nausea, during chemotherapy treatment among people treated with cannabinoids compared to placebo in a meta-analysis of 3 RCTs of low quality²²Smith LA, Azariah F, Lavender VT, Stoner NS, Bettiol S. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database or Systematic Reviews. 2015 Nov 12;2015(11):CD009464.
Less nausea and vomiting among children and adolescents with chemotherapy-induced nausea and vomiting with cannabinoid use compared to controls or baseline in a review of 22 studies of various designs²³Wong SS, Wilens TE. Medical cannabinoids in children and adolescents: a systematic review. Pediatrics. 2017 Nov;140(5). pii: e20171818.
A very weak trend toward less vomiting during chemotherapy treatment among people with cancer treated with dronabinol compared to placebo in a meta-analysis of a subset of 30 RCTs²⁴Machado Rocha FC, Stéfano SC, De Cássia Haiek R, Rosa Oliveira LM, Da Silveira DX. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. European Journal of Cancer Care (England). 2008 Sep;17(5):431-43.
Less refractory chemotherapy-induced nausea and vomiting (absence of emesis, use of rescue medications, absence of significant nausea, and summary scores for the Functional Living Index-Emesis) among people treated with 1 cycle of 1-4 self-titrated capsules of oral THC 2.5 mg/CBD 2.5 mg (TN-TC11M) 3 times daily, from days -1 to 5 compared to placebo in a small RCT;²⁵Grimison P, Mersiades A, Kirby A, et al. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. Annals of Oncology. 2020;31:1553-1560. a higher rate of adverse side effects was also seen, as noted in Safety and precautions ›

Compared to other therapies

Modest evidence of less vomiting among people treated with cannabinoids compared to neuroleptics (antipsychotic medication)

Modest evidence of comparable effects on nausea and vomiting among people treated with cannabinoids compared to prochlorperazine

Comparable chemotherapy-induced nausea and vomiting among people using cannabinoids compared to prochlorperazine in a systematic review of high methodological quality²⁶Schussel V, Kenzo L, Santos A, et al. Cannabinoids for nausea and vomiting related to chemotherapy: overview of systematic reviews. Phytotherapy Research. 2018;32:567-576.
Moderate quality evidence on the efficacy of cannabinoids compared to conventional antiemetics for chemotherapy-induced nausea and vomiting in systematic reviews of RCTs;²⁷Tafelski S, Häuser W, Schäfer M. Efficacy, tolerability, and safety of cannabinoids for chemotherapy-induced nausea and vomiting—a systematic review of systematic reviews. Schmerz. 2016;30:14-24. this study also found that pharmaceutical cannabinoids were less tolerated and less safe than conventional antiemetics, as noted in Safety and precautions ›
No difference in the number of people reporting nausea and vomiting during chemotherapy treatment among people treated with cannabinoids compared to prochlorperazine in a meta-analysis of 5 RCTs of low quality²⁸Smith LA, Azariah F, Lavender VT, Stoner NS, Bettiol S. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database or Systematic Reviews. 2015 Nov 12;2015(11):CD009464.
Less vomiting during chemotherapy treatment among people with cancer treated with dronabinol compared to neuroleptics in a meta-analysis of a subset of 30 RCTs²⁹Machado Rocha FC, Stéfano SC, De Cássia Haiek R, Rosa Oliveira LM, Da Silveira DX. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. European Journal of Cancer Care (England). 2008 Sep;17(5):431-43.
A weak trend toward less vomiting during chemotherapy treatment among people with cancer treated with nabilone compared to neuroleptics in a meta-analysis of a subset of 30 RCTs³⁰Machado Rocha FC, Stéfano SC, De Cássia Haiek R, Rosa Oliveira LM, Da Silveira DX. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. European Journal of Cancer Care (England). 2008 Sep;17(5):431-43.
Less chemotherapy-induced nausea and vomiting among people treated with oral cannabis compared to placebo or other treatments in a meta-analysis of 5 RCTs³¹Chow R, Valdez C, Chow N, et al. Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting—a systematic review and meta-analysis. Supportive Care in Cancer. 2020;28:2095-2103.

Neurological symptoms

Modest evidence of lower neuropathic pain scores among people with pain treated with THC/CBD or THC alone

Pain

Modest evidence of less cancer-related pain among people treated with either cannabis or some cannabinoids

Insufficient (conflicting) evidencepreclinical evidence only OR clinical studies with such poor or unclear methodology that no conclusion can be drawn OR conflicting findings across clinical studies with no preponderance of evidence in one direction; conflicting evidence occurs when studies find conflicting effects (positive effect vs no effect or negative effect) with the same treatment and the same general study population (same cancer type, for example) (this is the CancerChoices definition; other researchers and studies may define this differently) of an effect on pain among people treated with opioids when adding cannabinoids in combined analyses of studies

Quality of life and function

Modest evidence of a very small improvement in physical functioning but no evidence of an effect on quality of life among people with chronic pain or cancer treated with cannabis or cannabinoids

Sleep disruption

Insufficient evidence of better sleep quality among people with cancer or chronic pain treated with oral cannabis or cannabinoids

Symptoms not specific to cancer

Modest evidence of fewer anxiety symptoms among people with non-cancer medical conditions treated with pharmaceutical THC either with or without CBD

Good evidence of lower pain scores among people with pain treated with cannabis or cannabinoids

Modest evidence of less opioid use among people receiving opioid treatment for chronic pain also treated with medical cannabis for at least 30 days

Anxiety: modest evidence of fewer anxiety symptoms among people with non-cancer medical conditions treated with pharmaceutical THC either with or without CBD

Fewer anxiety symptoms among people with non-cancer medical conditions (primarily chronic non-cancer pain and multiple sclerosis) treated with pharmaceutical THC either with or without CBD compared to controls in a meta-analysisa statistical analysis that combines the results of two or more research studies; the results of smaller research studies addressing the same or similar questions can be analyzed as though they are one bigger, more powerful study of 31 RCTsrandomized controlled trial, a study design in which people are randomly assigned to either an experimental group or a control group to compare the outcomes from different treatments; an RCT is considered a strong design for determining a therapy’s effects and other clinical trials of low quality⁵³Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, Farrell M, Degenhardt L. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2019 Dec;6(12):995-1010.

Pain

Good evidence of lower pain scores among people with pain treated with cannabis or cannabinoids

Modest evidence of less opioid use among people receiving opioid treatment for chronic pain also treated with medical cannabis for at least 30 days

Moderately lower pain scores among people with pain—the majority with neuropathic pain—treated with synthetic cannabinoids exclusively THC compared to controls in a meta-analysis of 6 RCTs⁵⁴McDonagh MS, Morasco BJ et al. Cannabis-based products for chronic pain: a systematic review. Annals of Internal Medicine. 2022 Jun 7.
Lower pain from physical damage (nociceptive pain) among people treated with oral standardized cannabis extract compared to controls in a meta-analysis of 25 RCTs⁵⁵Rabgay K, Waranuch N et al. The effects of cannabis, cannabinoids, and their administration routes on pain control efficacy and safety: a systematic review and network meta-analysis. Journal of the American Pharmacists Association. 2020 Jan-Feb;60(1):225-234.e6.
Less opioid use (greater reduction in use) among people receiving opioid treatment for chronic pain also treated with medical cannabis for at least 30 days compared to less than 30 days in a very large observational study⁵⁶Nguyen T, Li Y, Greene D, Stancliff S, Quackenbush N. Changes in prescribed opioid dosages among patients receiving medical cannabis for chronic pain, New York State, 2017-2019. JAMA Network Open. 2023 Jan 3;6(1):e2254573.
Conclusive or substantial evidence that cannabis or cannabinoids are effective for treating pain in adults in a systematic review of recent (at that time) medical literature⁵⁷Abrams DI. The therapeutic effects of cannabis and cannabinoids: an update from the National Academies of Sciences, Engineering and Medicine report. European Journal of Internal Medicine. 2018 Mar;49:7-11.

Reducing cancer risk

Is cannabis or cannabinoids linked to lower risks of developing cancer or of recurrence? We present the evidence.

Head, neck, and oral cancer

No evidence of an effectoverall, one or more studies did not demonstrate that a treatment or intervention led to an expected outcome; this does not always mean that there is no effect in clinical practice, but that the studies may have been underpowered (too few participants) or poorly designed. Larger, well-designed studies provide more confidence in making assessments. on cancer recurrence of oropharynx squamous cell carcinoma among people using cannabis in a preliminary study

No evidence of an effect on risk of head and neck squamous cell carcinoma among people using cannabis

Keep reading about cannabis and cannabinoids

See all our reviews of complementary therapies

Authors

Nancy Hepp, MS

Lead Researcher

View profile

Laura Pole, MSN, RN, OCNS

Senior Clinical Consultant

View profile

Reviewer

Teresa Martin

Integrative patient advocate

View profile

Last update: November 2, 2024

Last full literature review: October 2021

We are grateful to integrative oncologist and CancerChoices advisor Donald Abrams, MD, for his generous sharing of research articles and commentary.

CancerChoices provides information about integrative in cancer care, a patient-centered approach combining the best of conventional care, self care and evidence-informed complementary care in an integrated plan cancer care. We review complementaryin cancer care, complementary care involves the use of therapies intended to enhance or add to standard conventional treatments; examples include supplements, mind-body approaches such as yoga or psychosocial therapy, and acupuncture therapies and self-care lifestyle actions and behaviors that may impact cancer outcomes; examples include eating health-promoting foods, limiting alcohol, increasing physical activity, and managing stress practices to help patients and professionals explore and integrate the best combination of conventionalthe cancer care offered by conventionally trained physicians and most hospitals; examples are chemotherapy, surgery, and radiotherapy and complementary therapies and practices for each person.

Our staff have no financial conflicts of interest to declare. We receive no funds from any manufacturers or retailers gaining financial profit by promoting or discouraging therapies mentioned on this site.

CancerChoices and BCCT Take: Cannabis and Head and Neck Cancer

References[+]

1	Guggisberg J, Schumacher M, Gilmore G, Zylla DM. Cannabis as an anticancer agent: a review of clinical data and assessment of case reports. Cannabis and Cannabinoid Research. 2021 Aug 7.
2	Johnson S, Ziegler J, August DA. Cannabinoid use for appetite stimulation and weight gain in cancer care: Does recent evidence support an update of the European Society for Clinical Nutrition and Metabolism clinical guidelines? Nutrition in Clinical Practice. 2021 Aug;36(4):793-807; Abrams DI. The therapeutic effects of cannabis and cannabinoids: an update from the National Academies of Sciences, Engineering and Medicine report. European Journal of Internal Medicine. 2018 Mar;49:7-11.
3, 58	Zhang H, Xie M et al. Survival outcomes of marijuana users in p16 positive oropharynx cancer patients. Journal of Otolaryngology—Head and Neck Surgery. 2019 Sep 2;48(1):43.
4	Kenyon J, Liu W, Dalgleish A. Report of objective clinical responses of cancer patients to pharmaceutical-grade synthetic cannabidiol. Anticancer Research. 2018 Oct;38(10):5831-5835./
5	Twelves C, Short S, Wright S. A two-part safety and exploratory efficacy randomized double-blind, placebo-controlled study of a 1:1 ratio of the cannabinoids cannabidiol and delta-9-tetrahydrocannabinol (CBD:THC) plus dose-intense temozolomide in patients with recurrent glioblastoma multiforme (GBM). Journal of Clinical Oncology. 2017; 35(15 suppl):2046.
6	Guzmán M, Duarte MJ et al. A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. British Journal of Cancer. 2006;95(2):197-203.
7	Waissengrin B, Leshem Y et al. The use of medical cannabis concomitantly with immune checkpoint inhibitors in non-small cell lung cancer: a sigh of relief? European Journal of Cancer. 2023 Feb;180:52-61.
8	Jadoon KA, Ratcliffe SH et al. Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group pilot study. Diabetes Care. 2016 Oct;39(10):1777-86.
9	Newman TM, Krishnan LP, Lee J, Adami GR. Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage. Scientific Reports. 2019 Sep 3;9(1):12697.
10	Hardy J, Greer R et al. Phase IIb randomized, placebo-controlled, dose-escalating, double-blind study of cannabidiol oil for the relief of symptoms in advanced cancer (MedCan1-CBD). Journal of Clinical Oncology. 2022 Nov 21:JCO2201632.
11, 57	Abrams DI. The therapeutic effects of cannabis and cannabinoids: an update from the National Academies of Sciences, Engineering and Medicine report. European Journal of Internal Medicine. 2018 Mar;49:7-11.
12	Mücke M, Carter C et al. Cannabinoide in der palliativen Versorgung: Systematische Übersicht und Metaanalyse der Wirksamkeit, Verträglichkeit und Sicherheit [Cannabinoids in palliative care: systematic review and meta-analysis of efficacy, tolerability and safety]. Schmerz. 2016 Feb;30(1):25-36. German; Mücke M, Weier M. Systematic review and meta-analysis of cannabinoids in palliative medicine. Journal of Cachexia, Sarcopenia and Muscle. 2018 Apr;9(2):220-234.
13, 18, 40, 45, 49	Mücke M, Carter C et al. Cannabinoide in der palliativen Versorgung: Systematische Übersicht und Metaanalyse der Wirksamkeit, Verträglichkeit und Sicherheit [Cannabinoids in palliative care: systematic review and meta-analysis of efficacy, tolerability and safety]. Schmerz. 2016 Feb;30(1):25-36. German.
14	Johnson S, Ziegler J, August DA. Cannabinoid use for appetite stimulation and weight gain in cancer care: Does recent evidence support an update of the European Society for Clinical Nutrition and Metabolism clinical guidelines? Nutrition in Clinical Practice. 2021 Aug;36(4):793-807; Abrams DI. The therapeutic effects of cannabis and cannabinoids: an update from the National Academies of Sciences, Engineering and Medicine report. European Journal of Internal Medicine. 2018 Mar;49:7-11.
15	Brisbois TD, de Kock IH et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Annals of Oncology. 2011 Sep;22(9):2086-2093.
16	Grimison P, Mersiades A et al. Oral cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: final results of a randomized, placebo-controlled, phase II/III trial. Journal of Clinical Oncology. 2024 Aug 16:JCO2301836.
17, 31	Chow R, Valdez C, Chow N, et al. Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting—a systematic review and meta-analysis. Supportive Care in Cancer. 2020;28:2095-2103.
19, 27	Tafelski S, Häuser W, Schäfer M. Efficacy, tolerability, and safety of cannabinoids for chemotherapy-induced nausea and vomiting—a systematic review of systematic reviews. Schmerz. 2016;30:14-24.
20, 26	Schussel V, Kenzo L, Santos A, et al. Cannabinoids for nausea and vomiting related to chemotherapy: overview of systematic reviews. Phytotherapy Research. 2018;32:567-576.
21	Mücke M, Weier M. Systematic review and meta-analysis of cannabinoids in palliative medicine. Journal of Cachexia, Sarcopenia and Muscle. 2018 Apr;9(2):220-234.
22, 28	Smith LA, Azariah F, Lavender VT, Stoner NS, Bettiol S. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database or Systematic Reviews. 2015 Nov 12;2015(11):CD009464.
23	Wong SS, Wilens TE. Medical cannabinoids in children and adolescents: a systematic review. Pediatrics. 2017 Nov;140(5). pii: e20171818.
24, 29, 30	Machado Rocha FC, Stéfano SC, De Cássia Haiek R, Rosa Oliveira LM, Da Silveira DX. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. European Journal of Cancer Care (England). 2008 Sep;17(5):431-43.
25	Grimison P, Mersiades A, Kirby A, et al. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. Annals of Oncology. 2020;31:1553-1560.
32, 36, 38, 55	Rabgay K, Waranuch N et al. The effects of cannabis, cannabinoids, and their administration routes on pain control efficacy and safety: a systematic review and network meta-analysis. Journal of the American Pharmacists Association. 2020 Jan-Feb;60(1):225-234.e6.
33, 46, 54	McDonagh MS, Morasco BJ et al. Cannabis-based products for chronic pain: a systematic review. Annals of Internal Medicine. 2022 Jun 7.
34	Hsu K, Whitham E, Kichenadasse G. Potential role of cannabidiol for seizure control in a patient with recurrent glioma. Journal of Clinical Neuroscience. 2020 Jan;71:275-276.
35, 44, 47	Wang L, Hong PJ et al. Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials. BMJ. 2021 Sep 8;374:n1034.
37	Boland EG, Bennett MI, Allgar V, Boland JW. Cannabinoids for adult cancer-related pain: systematic review and meta-analysis. BMJ Support Palliat Care. 2020 Mar;10(1):14-24.
39	Mücke M, Carter C et al. Cannabinoide in der palliativen Versorgung: Systematische Übersicht und Metaanalyse der Wirksamkeit, Verträglichkeit und Sicherheit [Cannabinoids in palliative care: systematic review and meta-analysis of efficacy, tolerability and safety]. Schmerz. 2016 Feb;30(1):25-36. German; Mücke M, Weier M. Systematic review and meta-analysis of cannabinoids in palliative medicine. Journal of Cachexia, Sarcopenia and Muscle. 2018 Apr;9(2):220-234.
41, 48	Häuser W, Welsch P, Klose P, Radbruch L, Fitzcharles MA. Efficacy, tolerability and safety of cannabis-based medicines for cancer pain : a systematic review with meta-analysis of randomised controlled trials. Schmerz. 2019 Oct;33(5):424-436. English
42, 43, 51	Noori A, Miroshnychenko A et al. Opioid-sparing effects of medical cannabis or cannabinoids for chronic pain: a systematic review and meta-analysis of randomised and observational studies. BMJ Open. 2021 Jul 28;11(7):e047717.
50	Mücke M, Weier M. Systematic review and meta-analysis of cannabinoids in palliative medicine. Journal of Cachexia, Sarcopenia and Muscle. 2018 Apr;9(2):220-234.
52	Abrams DI. The therapeutic effects of cannabis and cannabinoids: an update from the National Academies of Sciences, Engineering and Medicine report. European Journal of Internal Medicine. 2018 Mar;49:7-11.
53	Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, Farrell M, Degenhardt L. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2019 Dec;6(12):995-1010.
56	Nguyen T, Li Y, Greene D, Stancliff S, Quackenbush N. Changes in prescribed opioid dosages among patients receiving medical cannabis for chronic pain, New York State, 2017-2019. JAMA Network Open. 2023 Jan 3;6(1):e2254573.
59	Ghasemiesfe M, Barrow B, Leonard S, Keyhani S, Korenstein D. Association between marijuana use and risk of cancer: a systematic review and meta-analysis. JAMA Network Open. 2019 Nov 1;2(11):e1916318.

Cannabis and Cannabinoids (Marijuana)

How can cannabis and cannabinoids help you? What the research says

Improving treatment outcomes

Optimizing your body terrain

Managing side effects and promoting wellness

Reducing cancer risk

Keep reading about cannabis and cannabinoids

Authors

Nancy Hepp, MS

Laura Pole, MSN, RN, OCNS

Reviewer

Teresa Martin

Learn more

Getting a Clear Picture of Research on Cancer Therapies

Electroacupuncture

CancerChoices and BCCT Take: Cannabis and Head and Neck Cancer